Raymond James Financial
ARCT icon

Raymond James Financial’s Arcturus Therapeutics ARCT Stock Holding History

Raymond James Financial’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.3K Buy
+14,323
New +$113K ﹤0.01% 5178
2025
Q4 		– Sell
-11,553
Closed -$213K – 5168
2025
Q3 		$213K Sell
11,553
-551
-5% -$8.85K ﹤0.01% 4596
2025
Q2 		$157K Hold
12,104
– – ﹤0.01% 4636
2025
Q1 		$128K Buy
+12,104
New +$192K ﹤0.01% 4508

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Raymond James Financial's ARCT Position: Q2 2026 in Review

Raymond James Financial opened a new position in Arcturus Therapeutics (ARCT) in Q2 2026: 14,323 shares worth $96.3K. The stake represents ﹤0.01% of the portfolio and ranks #5178 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in ARCT as recently as Q3 2025.

Raymond James Financial first reported a position in ARCT in Q1 2025 and has held it in 4 quarters since. The position peaked at $213K in Q3 2025. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Raymond James Financial held 14,323 shares of Arcturus Therapeutics worth $96.3K as of Q2 2026.
  • Arcturus Therapeutics was a new Raymond James Financial position in Q2 2026.
  • Arcturus Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5178 holding.
  • Raymond James Financial first reported a position in Arcturus Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Raymond James Financial's Arcturus Therapeutics position peaked at $213K in Q3 2025.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.